A trial looking at alvespimycin for advanced cancer (PH1/102)

Cancer type:

All cancer types




Phase 1

This trial looked at a drug called alvespimycin (17-DMAG) for advanced solid tumours (not a leukaemia or lymphoma). This trial was supported by Cancer Research UK.

Alvespimycin is a type of biological therapy called a heat shock protein inhibitor. Heat shock proteins (HSP) are involved with cell growth. Alvespimycin stops a HSP called HSP90 working properly. Researchers thought that if they could stop HSP90 working, they could help stop cancer growing.

The aims of the trial were to

  • Find the best dose of alvespimycin to give
  • See what effect it has on proteins in the body
  • Find out how well it works as an anti cancer treatment

Summary of results

The research team found the best dose of alvespimycin to give. They also found that it was safe, and that it did affect the level of some proteins in the body.

This early phase trial recruited 25 people with an advanced solid tumour (not a leukaemia or lymphoma). They had already had the standard treatments available for their cancer type.

Everyone taking part had alvespimycin through a drip into a vein once a week. The first few people taking part had the lowest dose of alvespimycin. As they had no serious side effects, the next few people had a higher dose. And so on, until the research team found the best dose to give. This is called a dose escalation trial.  

There were 6 dose levels in this trial. Some people who had the highest dose level had serious side effects, so the research team concluded that the 5th dose level they tested was the best one to use.

The side effects included

  • Dry eyes
  • Blurred vision
  • Inflammation of the eye (conjunctivitis)
  • Damage to the surface of the eye (corneal abrasion)
  • Change in liver function tests

The research team also looked at how well the treatment worked. They were able to assess this in 20 of the people who took part. They found that

  • 1 person’s cancer went away
  • 1 person’s cancer got smaller
  • 9 people’s cancer stayed the same (in 3 of these people it stayed the same for longer than 6 months)
  • 9 people’s cancer continued to grow

The trial team concluded that they had found the best dose of alvespimycin to give, and that it was a potential treatment for cancer.

We have based this summary on information from the team who ran the trial.  The information they sent us has been reviewed independently (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof I Judson

Supported by

Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)

Other information

This is Cancer Research UK trial number CRUKD/06/052.

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 675

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think